GE HealthCare Technologies Inc. (GEHC)
| Market Cap | 31.42B -6.0% |
| Revenue (ttm) | 21.27B +6.5% |
| Net Income | 1.99B -11.4% |
| EPS | 4.34 -11.1% |
| Shares Out | 451.69M |
| PE Ratio | 16.03 |
| Forward PE | 13.51 |
| Dividend | $0.16 (0.23%) |
| Ex-Dividend Date | Oct 23, 2026 |
| Volume | 3,116,206 |
| Open | 71.10 |
| Previous Close | 70.35 |
| Day's Range | 69.45 - 71.32 |
| 52-Week Range | 58.75 - 89.77 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 82.70 (+18.87%) |
| Earnings Date | Oct 28, 2026 |
About GEHC
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, an... [Read more]
Financial Performance
In 2025, GEHC's revenue was $20.63 billion, an increase of 4.84% compared to the previous year's $19.67 billion. Earnings were $2.08 billion, an increase of 4.57%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for GEHC stock is "Buy." The 12-month stock price target is $82.7, which is an increase of 18.87% from the latest price.
News
GE HealthCare announces publication of research on End-tidal Control software
GE HealthCare (GEHC) announced the publication of research conducted at the University of Michiganiv evaluating the use of End-tidal Control software across a large multisite academic health system in...
Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michiganiv evaluating the use of End-tidal Control software across a l...
GE HealthCare’s MINItrace Magni achieves CE Mark, PETtrace expands
GE HealthCare (GEHC) announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 production....
GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-6...
GE HealthCare price target lowered to $75 from $79 at BTIG
BTIG analyst Ryan Zimmerman lowered the firm’s price target on GE HealthCare (GEHC) to $75 from $79 and keeps a Buy rating on the shares as part of a broader…
GE HealthCare to announce third quarter 2026 results on October 28, 2026
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team ...
GE HealthCare initiated with an Overweight at Barclays
Barclays initiated coverage of GE HealthCare (GEHC) with an Overweight rating and $85 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive…
GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business
Medical device maker GE HealthCare said on Monday it would buy privately held Sofie Biosciences for $945 million in cash, in a move that strengthens its ability to manufacture and distribute PET ima...
GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition
GE Healthcare Technologies will purchase radiopharmaceutical company Sofie Biosciences to expand into a lucrative therapeutic area.
GE HealthCare to acquire SOFIE Biosciences for $945M in cash
GE HealthCare (GEHC) announced a definitive agreement to acquire SOFIE Biosciences, a U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945M paid in c...
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North ...
GE Healthcare expected to buy Sofie for $945M in cash, WSJ reports
GE HealthCare (GEHC) is expected to announce Monday that it is acquiring Sofie Biosciences for $945M in cash, expanding its pharmaceutical diagnostics portfolio with PET tracer agents used in medical…
GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical imaging procedures like PET scans
The deal expands GE HealthCare's footprint in radiopharmaceuticals, its fastest-growing segment.
GE HealthCare price target lowered to $71 from $75 at Citi
Citi lowered the firm’s price target on GE HealthCare (GEHC) to $71 from $75 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology…
GE HealthCare raises quarterly dividend 14% to 4c per share
The Board of Directors of GE HealthCare (GEHC) Technologies declared a cash dividend of 4c per share of common stock for the third quarter of 2026, an increase of 14%…
GE HealthCare announces cash dividend increase for third quarter of 2026
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.04 per share of Common Stock for the third quarter of 2026, an i...
GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the appointment of Pascal Desroches, Senior Executive Vice President and Chief Financial Officer (CFO) of AT&T (NYSE: T), a Fortu...
Needham starts GE HealthCare with a Buy, sees attractive risk/reward
As previously reported, Needham initiated coverage of GE HealthCare (GEHC) with a Buy rating and $93 price target Shares at current levels are “largely pricing in a Bear case,” which…
GE HealthCare initiated with a Buy at Needham
Needham initiated coverage of GE HealthCare (GEHC) with a Buy rating and $93 price target
GE HealthCare announces CareIntellect for Operations
GE HealthCare (GEHC) announced CareIntellect for Operations, a new AI-enabled Software-as-a-Service application designed to help health systems forecast capacity constraints up to 72 hours in advance,...
GE HealthCare Announces CareIntellect for Operations, Helping Health Systems Optimize Resources and Expand Access to Care
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced CareIntellect™ for Operations, a new AI-enabled Software-as-a-Service (SaaS) application designed to help health systems forecast...
GE HealthCare in advanced talks to buy Sofie for $1B, FT reports
GE HealthCare (GEHC) is in advanced talks to acquire radiopharmaceutical developer Sofie Biosciences for roughly $1B, expanding its pharmaceutical diagnostics and cancer-imaging capabilities as it see...
GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports
GE HealthCare Technologies is in talks over a possible $1 billion deal to buy radiopharmaceutical developer Sofie Biosciences, the Financial Times reported on Sunday citing people familiar with the...
GE HealthCare Technologies Transcript: Wells Fargo 21st Annual Healthcare Conference
Q2 saw 11% order growth and a strong backlog, with new products and robust demand supporting future quarters. Margins are set to improve in the second half, while China stabilizes and PDX outperforms expectations. Strategic review updates and new product contributions are expected in 2027.
GE HealthCare announces StarGuide GX is 510k pending with U.S. FDA
GE HealthCare (GEHC) announced that StarGuide GX, its new digital 4D CZT SPECT/CT technology, is 510(k) pending with the U.S. Food and Drug Administration, FDA. This milestone is a step…